Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print September 3, 2008
(Neurology 2008, doi:10.1212/01.wnl.0000327339.55844.1a)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Chaturvedi, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaturvedi, S.
Received November 6, 2007
Accepted May 2, 2008

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

S. Chaturvedi MD*, J. Zivin MD, PhD, A. Breazna PhD, P. Amarenco MD, A. Callahan MD, L. B. Goldstein MD, M. Hennerici MD, H. Sillesen MD, A. Rudolph PhD, M. A. Welch MD, PhD, For the SPARCL Investigators

From Wayne State University (S.C.), Detroit, MI; University of California (J.Z.), San Diego; Pfizer (A.B., A.R.), New York, NY; Denis Diderot University (P.A.), Paris, France; Neurologic Consultants (A.C.), Nashville, TN; Duke University Medical Center (L.B.G.), Durham, NC; University of Heidelberg (M.H.), Mannheim, Germany; University of Copenhagen (H.S.), Denmark; and Rosalind Franklin University of Medicine and Science (M.A.W.), North Chicago, IL.


* To whom correspondence should be addressed. E-mail: SChaturv{at}med.wayne.edu.

Background: It is unclear whether patients age 65 years and over with a recent stroke or TIA benefit from statin treatment to a similar degree as younger patients.

Methods: The 4,731 patient cohort in the SPARCL study was divided into an elderly group (65 and over) and a younger group. The primary endpoint (fatal or nonfatal stroke) and secondary endpoints were analyzed, with calculation of the hazard ratio (HR) and p values from a Cox regression model.

Results: There were 2,249 patients in the elderly group and 2,482 in the younger group. The baseline LDL (133 mg/dL) and total cholesterol were comparable in the two groups. The elderly and younger groups had a 61.4 mg/dL and 58.7 mg/dL decrease in mean LDL during the trial. The primary endpoint was reduced by 26% in younger patients (HR 0.74, 0.57–0.96, p = 0.02) and by 10% in elderly subjects (HR 0.90, 0.73–1.11, p = 0.33). A test of heterogeneity for a treatment–age interaction was not significant (p = 0.52). The risk of stroke or TIA (HR 0.79, p = 0.01), major coronary events (HR 0.68, p = 0.035), any coronary heart disease event (HR 0.61, p = 0.0006), and revascularization procedures (HR 0.55, p = 0.0005) was reduced in the elderly group.

Conclusions: There was no heterogeneity in the stroke reduction seen with atorvastatin in the elderly and younger groups. Cardiac events and revascularization procedures were also lower in both the elderly and younger subgroups treated with atorvastatin. These results support the use of atorvastatin in elderly patients with recent stroke or TIA.




Correspondence:

Read all Correspondence

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack
Luca Mascitelli, et al.
Neurology Online, 21 Nov 2008 [Full text]
Reply from the author
Seemant Chaturvedi
Neurology Online, 21 Nov 2008 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by AAN Enterprises, Inc.